Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
This research investigates participant satisfaction with subcutaneous SC ocrelizumab treatment in people with Multiple Sclerosis MS. It focuses on measuring satisfaction after 12 months of therapy using a specialized questionnaire called the Therapy Administration Satisfaction Questionnaire Subcutaneous TASQ-SC. The study also examines changes and correlations in neurofilament light chain NfL protein levels, a marker related to MS disease activity. Participants who are receiving ocrelizumab SC injections for the first time as part of their routine MS treatment will be observed for up to 12 months. The treatment is given according to the physicians discretion and local clinical practice. Throughout the study, participant satisfaction with the SC injection will be assessed at baseline, 6 months, and 12 months. Blood samples will be collected at these time points to measure NfL protein levels and analyze their relationship to MS relapses, disability scores, prior therapies, and other health factors. During the study, participants will complete satisfaction questionnaires and undergo blood tests at scheduled visits. Researchers will monitor adverse events and track various health indicators including MRI lesion counts and other biomarkers. The main outcome is participant satisfaction at 12 months, with additional assessments at earlier time points. This observational study lasts up to one year, with ongoing collection of safety and disease activity data during that time.
Actively Recruiting
Researchers are conducting a prospective, observational study to collect real-world evidence on the use and dose adjustment of SL-APO sublingual apomorphine for treating OFF episodes in Parkinsons disease. The study aims to understand how SL-APO is used in practice, focusing on dose titration, individual dose determination, and how these factors influence patient satisfaction, treatment continuation, and the balance between effectiveness and safety. Participants start with a 10 mg dose of SL-APO during an OFF episode and undergo dose titration at home if the initial response is insufficient. Dose adjustments occur in 5 mg increments up to a maximum of 30 mg per dose, with no more than five doses daily and a minimum 2-hour interval between doses. The study includes a baseline visit, titration follow-up visits which may be calls or on-site, and maintenance dose tracking using patient diaries. Follow-up visits occur at 3 and 6 months, with the 6-month visit marking the studys end. During the study, participants keep a Patient Titration Diary from the second SL-APO intake until titration ends and then a Patient Maintenance Diary until study completion. Diaries document daily intake for the first week with at least 10 doses, then weekly entries. Researchers collect data on dose usage, dose adjustments, and patient outcomes without additional procedures beyond routine care. The primary outcome is identifying the most frequent dose used after adjustment, with safety and efficacy monitored through regular follow-ups over six months.